Date: 2015-08-20
Type of information: Collaboration agreement
Compound: SkinVision App
Company: Leo Pharma (Denmark) SkinVision (The Netherlands)
Therapeutic area: Technology - Services - Cancer - Oncology - Dermatological diseases
Type agreement: collaboration
Action mechanism:
Disease: melanoma
Details: * On August 20, 2015, Leo Pharma, a global healthcare company dedicated to helping people achieve healthy skin, announced an investment in privately owned SkinVision, a derma focused mobile app company based in Amsterdam, Netherlands. This agreement is one in a series of recent deals for LEO Pharma and illustrates the company’s ambition to provide easy access to better care solutions for people with skin diseases. SkinVision is known for its early self-detection skin assessment app for smartphones. The SkinVision App works by users taking pictures of moles, which are then analysed using an algorithm to identify potential abnormal growth. The app evaluates the risk level with an online assessment based on a traffic light of red, orange or green. Characteristics of unnatural growth could indicate a developing melanoma (code red), or if further research is needed (code orange). In both cases, the patient is referred to a dermatologist. Users can archive their skin lesions to track for changes over time or can share the images with their doctor through the app when they feel uncomfortable. The application has received European CE certification, following its scientific testing by the university clinic of Ludwig Maximillian University (LMU) in Munich, Germany, in 2013. The current focus area of the app is melanoma – but is likely to expand into other skin disease areas. The overall agreement covers both an equity investment as well as a Letter of Intent outlining possible future collaboration projects. LEO Pharma has invested in SkinVision along with majority shareholder Personal Health Solutions (PHS) Capital, a Dutch investment firm focusing on science based, technology enabled solutions that provide an enhanced quality of life and reduces the risk of chronic illness. This agreement is one in a series of recent deals for LEO Pharma and illustrates the company’s ambition to provide easy access to better care solutions for people with skin diseases. The overall agreement covers both an equity investment as well as a Letter of Intent outlining possible future collaboration projects. LEO Pharma has invested in SkinVision along with majority shareholder Personal Health Solutions (PHS) Capital, a Dutch investment firm focusing on science based, technology enabled solutions that provide an enhanced quality of life and reduces the risk of chronic illness.
Financial terms:
Latest news:
